Introduction: Adalimumab, an anti-tumor
INTRODUCTION
Adalimumab (Humira Ò ; AbbVie, North Chicago, IL, USA) is a fully human, highly specific, high-affinity anti-tumor necrosis factor a monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA) as well as other immunemediated inflammatory diseases in over 90 countries worldwide [1] [2] [3] .
Adalimumab is administered via subcutaneous injection. In placebo-controlled clinical trials in adult patients with RA, the most common adverse event (AE) with adalimumab was injection site reactions, including erythema and/ or itching, hemorrhage, related pain, and swelling [4] [5] [6] [7] [8] . The overall incidence of such reactions was 20.3% in patients who received adalimumab versus 13 .8% who received placebo;
these reactions are the most commonly reported AE across all indications [4] .
Pain related to subcutaneous injection can be influenced by various factors, including the inactive ingredients of the formulation (e.g., citrate buffer) [9] [10] [11] , injection volume [12, 13] , and needle size and sharpness [14] . A 40 mg/0.4 mL formulation of adalimumab was developed to address pain associated with injection. The active ingredient in both formulations remains adalimumab derived from the same master cell bank using identical isolation processes [15] . The 40 mg/0.4 mL formulation differs from the current formulation of adalimumab in that it has fewer excipients (Supplementary Table 1) ; particularly, there is no citrate buffer.
Further, the citrate-free formulation has a higher concentration of adalimumab that allows a smaller injection volume (40 mg adalimumab delivered in 0.4 mL instead of 0.8 mL), and the 40 mg/0.4 mL formulation is delivered via a syringe that has a smaller (29 vs 27 gauge) needle than the 40 mg/0.8 mL formulation.
This report details the results of two phase 2, randomized crossover studies in patients with RA that assessed injection site-related pain, safety, and tolerability of the 40 mg/0.4 mL adalimumab formulation versus the 40 mg/ 0.8 mL formulation.
METHODS

Study Designs
Two phase 2, randomized, single-blind, twoperiod crossover studies of identical design were conducted ( Fig. 1) 
Treatment
After a screening visit (within 30 days of baseline), patients were centrally randomized using an interactive voice response system/ interactive web response system in a 1:1 ratio to one of two sequences of adalimumab [either the 40 mg/0.8 mL or 40 mg/0.4 mL formulation at visit 1, followed by the other formulation at visit 2 in a blinded manner ( Fig. 1) ]. The timing of the second visit was based on the regularly scheduled doses of adalimumab required by the patient's prescribed on-label dosing schedule (eow or ew).
Assessments
Patients reported injection site pain on the four-item short-form McGill Pain Questionnaire (MPQ-SF) [18] , which included (1) 
Statistical Methods
Based on a prior investigation, it was reasonable to assume a mean pain level of 3.00 and 2.00 cm on the 10-cm VAS for 40 mg/0.8 mL and 40 mg/ 0.4 mL formulations, respectively, with a standard deviation of 2.60 for the difference. From this assumption, it was estimated that a two-sided level a = 0.05 test for superiority with 83% power would require a total of 60 patients.
Injection site pain was analyzed in the crossover intent-to-treat population, defined as all patients who were randomized and completed both periods and received study drug in each period of the study. The primary endpoint was the patient's immediate pain after injection on the VAS. The 95% confidence intervals (CI) and P values for the difference between 40 mg/0.8 mL and 40 mg/0.4 mL formulations were calculated using a two-period crossover analysis of variance (ANOVA) model with period, sequence, and treatment as fixed effects, and subject as a random effect. The same statistical model was also used for the pooled analysis of injection site pain and for continuous endpoints in the individual studies. The two identical studies were pooled to obtain a more reliable estimate of the treatment effect. The percent difference between the two formulations in immediate pain after injection was calculated for each patient and analyzed using descriptive statistics. Based on a minimal clinically important difference (MCID) of 1.3 cm in VAS immediately following injection [19] , the proportion of patients who achieved C1.3 cm less pain on the VAS while receiving the 40 mg/0.4 mL formulation than while receiving the 40 mg/0.8 mL formulation was calculated; a two-sided exact binomial test was performed to assess whether this proportion differed from 50%. AEs were summarized. Treatment-emergent AEs were defined as those that began on or after the first dose of study drug and up to 70 days after the last dose of study drug.
RESULTS
Patients
In Study 1, 71 patients were screened and 64
were randomized, 33 to the sequence of 40 mg/ 0.8 mL to 40 mg/0.4 mL formulation and 31 to the sequence of 40 mg/0.4 mL to 40 mg/0.8 mL formulation. In Study 2, 68 patients were screened and 61 were randomized, 31 and 30
to the respective sequences of 40 mg/0.8 mL to 40 mg/0.4 mL and 40 mg/0.4 mL to 40 mg/ 0.8 mL formulation (Fig. 2) . One randomized patient in each study discontinued before receiving the first dose of study drug; one patient in Study 1 discontinued (due to pharyngitis) after receipt of the first dose of study drug (Fig. 2 ).
Demographic and clinical characteristics at baseline within each study were similar between the sequence groups, with the exception of age and duration of RA in Study 1 ( Table 1) . ANOVA analysis of variance, cITT crossover intent-to-treat, RA rheumatoid arthritis, SD standard deviation a P\0.05 for difference between sequence groups using one-way ANOVA b Calculated as (date of first study drug-date of diagnosis of RA)/365.25 c P B 0.001 for difference between sequence groups using one-way ANOVA d Only for patients currently receiving adalimumab e Assessed on a 10-cm visual analog scale at screening (0 cm = no pain; 10 cm = worst possible pain)
Pain and Injection Site Assessment
Other Endpoints
Injection-related pain 15 min after injection was significantly lower for the 40 mg/0.4 mL versus the 40 mg/0.8 mL formulation in Study 2 but not in Study 1 (Table 3) . For the pooled population, the mean difference in pain 15 min (Table 3) .
A subgroup of patients (n = 55 in each study) were able to discern between the pain of the needle entering the skin and the pain from the injected solution for C1 of the injections. In both studies, more patients attributed pain with the 40 mg/0.8 mL formulation to the solution rather than to the needle. Conversely, more patients attributed pain with the 40 mg/0.4 mL formulation to needle entry than to the solution (Supplementary Table 2 ).
Study staff completed the Draize scale at 10 and 30 min after injection. In both studies and with both formulations, the majority of patients had no hemorrhage/petechiae, no or very slight erythema, and no or very slight edema; pruritus was rarely observed (Supplementary Tables 3, 4) . AE adverse event a n = 62; one patient discontinued the study before receiving the 40 mg/0.4 mL formulation
The MCID has been reported to range between 1.0 and 1.6 cm in settings of acute pain [19] [20] [21] , and between 0.5 and 1.1 cm in observational studies of chronic pain in patients with RA [22] .
Most other patient-reported endpoints were statistically significantly in favor of the 40 mg/ 0.4 mL formulation immediately after injection in Study 1 and at both time points after injection for Study 2. As observed for the primary and most other endpoints, differences between formulations were of larger magnitude in Study 2 compared with Study 1. The reasons for dissimilar pain ratings for these two identically designed studies are unclear, but they may relate to population differences where the studies were conducted (Belgium and the Czech Republic versus Australia, Canada, and Germany).
The MPQ-SF pain experience scale assesses both sensory and affective dimensions of the pain experience. It should be noted that differences that were observed between formulations were mainly related to sensory aspects of pain. Affective 
